Sinovac Biotech, a China-based vaccine manufacturer, has announced that its subsidiary, Sinovac Beijing, has completed its acquisition of buildings and land use rights for an extension of its production capacity.

Shanghai-based NOD Pharmaceuticals Inc. has announced that the U.S. Patent and Trademark Office has approved the patent application for its nano-particle oral delivery technology.

Sinovac Biotech, a developer and provider of vaccines in China, has received a certificate of approval from the Secretaria de Salud to distribute PANFLU.1, its H1N1 pandemic influenza (swine flu) vaccine, in Mexico.

Sinovac Biotech, a Chinese provider of biopharmaceutical products, has signed an agreement with Boryung Pharmaceutical Company, a Korean manufacturer of pharmaceuticals, to collaborate on marketing efforts and possible H1N1 vaccine supply to the South Korean government.

ONCO-Z Corious Versicolor Extract, which is produced by Hong Kong manufacturer PuraPharm International, recently became the first traditional Chinese medicine ingredient to become "USP Verified."

Shandong-based China Biologic Products, a leading plasma-related pharmaceutical company in China, has announced that one of its research projects, "High-Purity Human Albumin," will be listed in the National Torch Plan of China.

Sweden-based Orexo and the Chinese pharmaceutical company NovaMed Pharmaceuticals have signed an exclusive licensing and distribution agreement that grants NovaMed rights to seek approval for the marketing and distributing of Abstral Orexo´s product for treatment of breakthrough cancer pain in mainland China and, if granted, to market and sell the product in that market.

Chengdu-based Tianyin Pharmaceutical has received the production license of Tongbianling Capsules in dosage form of 0.25 gram per capsule and is due to market the new product in February 2009.

Wuxi PharmaTech has signed a new three-year, in vitro absorption, distribution, metabolism, and excretion collaboration agreement with Pfizer.

Harbin based China Sky One Medical, a pharmaceutical company producing over-the-counter drugs in the China recently obtained production approval from the Chinese State Food and Drug Administration for two of its newly developed drugs.